Pulmonary Arterial Hypertension (PAH) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Pulmonary Arterial Hypertension Emerging Therapy and TPP Insights

Thelansis’s “Pulmonary Arterial Hypertension (PAH) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Pulmonary Arterial Hypertension Overview

Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary arteries that raises vascular resistance and strains the right ventricle. Symptoms include exertional breathlessness, fatigue, dizziness, or syncope; advanced disease can cause right-sided heart failure. PAH can be idiopathic, heritable, or associated with connective-tissue disease. Treatment is guided by risk assessment and may combine endothelin-receptor antagonists, nitric oxide pathway drugs, and prostacyclin therapies. Sotatercept, an activin-signaling inhibitor, adds a fourth treatment pathway and is approved in the United States for adults to improve exercise capacity, functional class, and clinical outcomes. 2026 ERS guidance recommends considering add-on sotatercept for patients at intermediate-low, intermediate-high, or high risk despite PAH therapy, with specialist monitoring. Despite progress, disease progression and treatment-related risks persist, sustaining research into long-term outcomes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)